Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
DUBLIN, Ireland and TREVOSE, Pa., June 13, 2017 -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in the JMP Securities Life Science Conference. Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will take part in a panel discussion titled, “Developing and Commercializing Drugs for Rare Diseases,” on Tuesday, June 20 at 10:30 a.m. ET. The conference will take place at the St. Regis in New York, NY.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
